KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Current Taxes (2016 - 2022)

Pacira BioSciences has reported Current Taxes over the past 9 years, most recently at $11000.0 for Q2 2022.

  • For Q2 2022, Current Taxes changed N/A year-over-year to $11000.0; the TTM value through Jun 2022 reached $11000.0, changed N/A, while the annual FY2021 figure was $429000.0, 276.32% up from the prior year.
  • Current Taxes for Q2 2022 was $11000.0 at Pacira BioSciences, down from $863000.0 in the prior quarter.
  • Over five years, Current Taxes peaked at $1.7 million in Q1 2020 and troughed at $11000.0 in Q2 2022.
  • A 5-year average of $534200.0 and a median of $343000.0 in 2019 define the central range for Current Taxes.
  • On a YoY basis, Current Taxes climbed as much as 1970.51% in 2020 and fell as far as 91.45% in 2020.
  • Year by year, Current Taxes stood at $90000.0 in 2018, then skyrocketed by 1381.11% to $1.3 million in 2019, then tumbled by 91.45% to $114000.0 in 2020, then surged by 276.32% to $429000.0 in 2021, then tumbled by 97.44% to $11000.0 in 2022.
  • Business Quant data shows Current Taxes for PCRX at $11000.0 in Q2 2022, $863000.0 in Q1 2022, and $429000.0 in Q4 2021.